Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Pharmaceutics - NAPLEX

  1. A 78-year-old male (weight 72 kg) is admitted for aspiration pneumonia and is now receiving continuous enteral nutrition via nasogastric tube due to dysphagia after stroke. Current medications include phenytoin extended-release capsules 300 mg orally once daily, metoprolol tartrate immediate-release tablets 50 mg orally twice daily, and omeprazole delayed-release capsules 20 mg orally once daily; labs: SCr 1.0 mg/dL (0.6–1.3), AST 28 U/L (10–40), ALT 25 U/L (7–56), Na 138 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). The team requests a formulation change to provide phenytoin through the feeding tube with minimal risk of altered exposure while tube feeds continue. Which formulation is most appropriate for this patient?
    Answer: Switch to phenytoin oral suspension (immediate-release) administered via feeding tube with appropriate flushing and feed separation per protocol This question tests the appropriate selection of phenytoin formulations for enteral tube administration. The key patient-specific factor is the need for continuous enteral nutrition via nasogastric tube, which requires careful consideration of drug-food interactions and bioavailability. Phenytoin oral suspension (immediate-release) is the best choice because it can be safely administered via feeding tube with appropriate flushing protocols and feed separation to minimize binding to enteral nutrition proteins. Extended-release capsules cannot be opened and administered via tube as this would destroy the modified-release mechanism and potentially cause dose dumping. Crushing delayed-release tablets would similarly destroy the formulation's integrity, and sublingual tablets do not exist for phenytoin. The pharmaceutical pearl is that when converting between phenytoin formulations, dosing adjustments may be needed due to differences in bioavailability between salt forms, and proper tube flushing and feed separation (typically holding feeds 1-2 hours before and after administration) is essential to prevent reduced absorption.
  2. A 55-year-old woman (72 kg) brings in a new prescription for latanoprost ophthalmic solution for glaucoma. Current medications: latanoprost 0.005% eye drops 1 drop OU nightly, artificial tears PRN. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 22 U/L (10–40), ALT 20 U/L (7–56), Na 139 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). She asks where to store the bottle at home because her bathroom is most convenient. How should this medication be stored to maintain stability?
    Answer: Store unopened bottles refrigerated; after opening, store as directed by labeling (often room temperature) and protect from excessive heat and light This question tests storage guidelines for ophthalmic prostaglandin analogs to prevent degradation. The key patient-specific factor is the convenience preference for bathroom storage, which may expose to heat and humidity. Refrigerating unopened bottles and storing opened ones at room temperature protected from heat/light is best as it maintains chemical stability and prevents bacterial growth. Humid or sunny storage (choices B and D) accelerates degradation, while freezing (choice C) risks container damage or precipitation. Bathroom cabinet (choice B) introduces moisture. A pharmaceutical pearl is to protect light-sensitive eye drops from environmental factors to preserve potency. To ensure safety and efficacy, counsel on proper instillation and discard dates to avoid infections or reduced IOP control.
  3. A 59-year-old man (88 kg) with chronic pancreatitis reports oily stools and poor symptom control on an oral fat-soluble vitamin supplement. Current medications: pancrelipase delayed-release capsules with meals, multivitamin tablet daily. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 32 U/L (10–40), ALT 29 U/L (7–56), Na 138 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist is asked which factor most affects the bioavailability of fat-soluble vitamins in this patient. Which factor most affects this drug's bioavailability?
    Answer: Reduced bile acids and impaired micelle formation leading to decreased absorption This question explores bioavailability issues of lipophilic nutrients in malabsorptive conditions. The key patient-specific factor is chronic pancreatitis impairing bile acid production necessary for fat absorption. Reduced bile acids and impaired micelle formation is the main factor as it hinders solubilization and uptake of fat-soluble vitamins, leading to deficiencies. Increased gastric emptying or hepatic metabolism (choices B and C) do not primarily affect lipophilic absorption, and renal elimination (choice D) is irrelevant for vitamins reliant on GI uptake. Enhanced absorption (choice B) contradicts malabsorption pathology. A pharmaceutical pearl is to consider water-miscible formulations for fat-soluble vitamins in pancreatic insufficiency to improve bioavailability. For patient safety and efficacy, monitor vitamin levels and supplement accordingly to prevent deficiency-related complications.
  4. A 6-year-old girl (20 kg) with a documented dye allergy (FD&C Yellow No. 5) needs diphenhydramine for pruritus. Current medications: cetirizine 5 mg chewable tablet daily, hydrocortisone 1% cream BID PRN. Labs: SCr 0.4 mg/dL (0.3–0.7), AST 22 U/L (10–40), ALT 18 U/L (7–56), Na 140 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The prescriber requests a compounded oral liquid diphenhydramine 12.5 mg/5 mL without dyes or flavoring agents that commonly contain the allergen. What is the best compounding method for this preparation?
    Answer: Prepare an oral solution by dissolving diphenhydramine HCl USP powder in purified water and QS with dye-free, alcohol-free simple syrup vehicle This question tests the principles of compounding oral liquids for pediatric patients with specific allergen avoidance. The key patient-specific factor is the documented dye allergy (FD&C Yellow No. 5), necessitating a dye-free formulation. Preparing an oral solution from diphenhydramine HCl USP powder dissolved in purified water and quantified with dye-free, alcohol-free simple syrup is the best choice as it ensures solubility, stability, and allergen avoidance while providing an appropriate vehicle for pediatric dosing. Using dye-containing tablets or flavored vehicles (choice B) risks allergic reactions due to potential dye exposure, and oil-based suspensions (choice C) may not provide adequate drug dispersion or palatability. Capsule formulations (choice D) are unsuitable for a young child unable to swallow capsules and do not address liquid needs. A useful pharmaceutical pearl is to prioritize USP-grade ingredients in compounding to minimize impurities and allergens, enhancing safety. For efficacy and patient safety, always verify excipient compatibility with patient allergies during formulation design.
  5. A 29-year-old male (weight 80 kg) with type 1 diabetes requests counseling after picking up a new supply of insulin glargine (100 units/mL) prefilled pens. Current medications: insulin glargine pen 24 units subcutaneously nightly and insulin aspart pen with meals. Labs: SCr 0.8 mg/dL (0.6–1.3), AST 24 U/L (10–40), ALT 21 U/L (7–56), Na 137 mEq/L (135–145), K 4.3 mEq/L (3.5–5.0). He will be traveling for 2 weeks and asks how to store unopened and in-use pens to maintain stability. How should this medication be stored to maintain stability?
    Answer: Store unopened pens refrigerated; once in use, keep at room temperature within labeled in-use time and avoid excessive heat/light This question tests knowledge of insulin storage requirements to maintain stability. The key patient-specific factor is the need for proper storage during a 2-week travel period for both unopened and in-use insulin pens. The correct storage protocol is to keep unopened pens refrigerated (2-8°C) until first use, then store in-use pens at room temperature (below 30°C) for up to 28 days while protecting from excessive heat and light. Freezing insulin destroys its protein structure and renders it ineffective, making it unsafe for use. Storing all pens at room temperature indefinitely would lead to loss of potency beyond the labeled in-use time. Refrigerating in-use pens is unnecessary and may cause injection discomfort due to cold insulin. The pharmaceutical principle is that insulin stability depends on proper temperature control, and patients should be counseled to never freeze insulin, avoid extreme temperatures, and follow manufacturer-specific storage guidelines to ensure therapeutic efficacy.
  6. A 52-year-old woman (70 kg) with Roux-en-Y gastric bypass 2 years ago presents for uncontrolled hypothyroid symptoms. Current medications: levothyroxine 100 mcg tablet daily, calcium citrate 600 mg PO BID, omeprazole 20 mg delayed-release capsule daily. Labs: TSH 9.8 mIU/L (0.4–4.5), SCr 0.9 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 19 U/L (7–56), Na 139 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist suspects reduced absorption related to formulation and GI anatomy. Which factor most affects this drug's bioavailability in this patient?
    Answer: Reduced gastric acidity and altered dissolution of the solid oral dosage form This question examines factors influencing bioavailability of thyroid hormone replacements in patients with altered GI anatomy. The key patient-specific factor is the history of Roux-en-Y gastric bypass, which reduces stomach size and alters pH, impacting drug dissolution. Reduced gastric acidity and altered dissolution of the solid oral dosage form is the primary factor as levothyroxine requires acidic conditions for optimal absorption, which are diminished post-bypass. Increased first-pass metabolism (choice A) is unlikely without hepatic changes, and enhanced absorption or renal clearance (choices C and D) do not align with bypass physiology that typically decreases absorptive surface. Increased intestinal surface area (choice D) is incorrect as bypass reduces effective absorptive area. A generalizable pearl is to monitor thyroid function closely in bariatric patients and consider dose adjustments or liquid formulations for better absorption. To ensure safety and efficacy, educate patients on separating levothyroxine from interfering substances like calcium or PPIs.
  7. A 40-year-old female (weight 62 kg) with chronic plaque psoriasis is prescribed a high-potency topical corticosteroid for thick plaques on elbows and knees. Current medications: calcipotriene 0.005% cream twice daily and cetirizine 10 mg tablet daily. Labs: SCr 0.8 mg/dL (0.6–1.3), AST 17 U/L (10–40), ALT 15 U/L (7–56), Na 139 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). She states she dislikes greasy ointments and often skips them, but she wants effective delivery through hyperkeratotic lesions with fewer applications. What is the optimal drug delivery system for this patient?
    Answer: A topical ointment under occlusion because it enhances hydration and penetration through thick plaques This question tests selection of topical formulations for enhanced penetration through hyperkeratotic skin. The key patient-specific factor is thick psoriatic plaques on elbows and knees with poor adherence to greasy formulations. A topical ointment under occlusion is optimal because ointments provide the best penetration through thick plaques due to their occlusive properties, and adding plastic wrap occlusion further enhances hydration and drug penetration while potentially allowing less frequent application. Aqueous gels actually provide minimal occlusion and would have poor penetration through thick plaques. Systemic corticosteroids are inappropriate for chronic plaque psoriasis due to side effects and rebound risk. The pharmaceutical principle is that vehicle selection for topical therapy must match the skin condition - ointments and occlusion are preferred for thick, hyperkeratotic lesions despite patient preferences, and counseling about proper use and benefits may improve adherence.
  8. A 46-year-old woman (68 kg) with celiac disease reports variable response to an oral iron product. Current medications: ferrous sulfate 325 mg tablet daily, levothyroxine 75 mcg tablet daily. Labs: Hgb 10.2 g/dL (12–16), ferritin 8 ng/mL (15–150), SCr 0.8 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 18 U/L (7–56), Na 140 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist is asked which factor most affects oral iron bioavailability in this patient. Which factor most affects this drug's bioavailability?
    Answer: Decreased intestinal surface area and inflammation leading to reduced absorption This question investigates bioavailability barriers for minerals in autoimmune GI disorders. The key patient-specific factor is celiac disease causing villous atrophy and reduced absorptive surface. Decreased intestinal surface area and inflammation primarily affect iron absorption by limiting uptake sites, contributing to anemia. Increased gastric pH or reduced metabolism (choices B and C) may not directly impair iron, and enhanced bioavailability (choice C) contradicts malabsorption. Renal clearance (choice D) is not relevant for oral iron. A pharmaceutical pearl is to recommend parenteral iron if oral absorption is severely compromised in malabsorptive states. Emphasizing safety, separate iron from inhibitors like levothyroxine and monitor hemoglobin to ensure effective repletion without GI irritation.
  9. A 67-year-old woman (58 kg) with Parkinson disease has worsening tremor and cannot swallow solid dosage forms reliably. Current medications: carbidopa/levodopa immediate-release 25/100 mg tablet TID, sertraline 50 mg tablet daily, docusate 100 mg capsule BID. Labs: SCr 1.1 mg/dL (0.6–1.3), AST 30 U/L (10–40), ALT 27 U/L (7–56), Na 136 mEq/L (135–145), K 3.9 mEq/L (3.5–5.0). Her caregiver asks for a formulation that can be administered without tablets while maintaining immediate-release dosing. Which formulation is most appropriate for this patient?
    Answer: Switch to an orally disintegrating carbidopa/levodopa formulation (if available) or an immediate-release-compatible liquid/dispersion per labeling This question assesses formulation alternatives for Parkinson medications in patients with swallowing difficulties. The key patient-specific factor is unreliable swallowing of solid forms due to disease progression. Switching to an orally disintegrating or immediate-release liquid/dispersion formulation is most appropriate as it facilitates administration without altering pharmacokinetics, maintaining tremor control. Crushing extended-release or using enteric-coated forms (choices A and D) disrupts release profiles, potentially causing dose dumping or inefficacy, while chewing tablets (choice C) may not ensure complete absorption. Immediate-release tablets without modification (choice C) pose choking risks. A pharmaceutical pearl is to prioritize swallow-safe formulations in neurodegenerative diseases to prevent aspiration. For safety and efficacy, monitor for consistent symptom control and adjust doses based on clinical response.
  10. A 6-year-old female (weight 20 kg) is seen in clinic for acute otitis media and has a documented immediate hypersensitivity reaction to FD&C dyes (urticaria with dyed oral liquids). Current medications: cetirizine oral solution 5 mg/5 mL, 5 mL by mouth daily (dye-free); no other medications. Labs: SCr 0.4 mg/dL (0.3–0.7), AST 22 U/L (10–40), ALT 18 U/L (7–56), Na 140 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The prescriber wants amoxicillin 400 mg/5 mL but the available commercial suspension contains dye; the pharmacy will compound a dye-free oral liquid using amoxicillin capsules. What is the best compounding method for this preparation?
    Answer: Open amoxicillin capsules, triturate the powder, and reconstitute with a dye-free aqueous oral vehicle (e.g., Ora-Blend SF/Ora-Sweet SF) to the desired concentration This question evaluates compounding methods for preparing a dye-free oral liquid formulation. The key patient-specific factor is the documented immediate hypersensitivity reaction to FD&C dyes, requiring a dye-free preparation. Opening amoxicillin capsules and triturating the powder with reconstitution in a dye-free aqueous vehicle (Ora-Blend SF/Ora-Sweet SF) is the most appropriate method as it maintains drug stability while avoiding dyes and provides proper suspending properties. Crushing capsules with mineral oil would create an inappropriate oleaginous preparation that could affect absorption and palatability. Dissolving capsule shells in hot water is unnecessary and could degrade the drug, while alcohol-based solutions are inappropriate for pediatric patients and could cause irritation. The pharmaceutical principle is that when compounding for patients with dye sensitivities, using certified dye-free vehicles ensures safety while maintaining appropriate pharmaceutical properties including stability, palatability, and bioavailability.
  11. A 16-year-old boy (60 kg) with ADHD is having difficulty remembering a midday dose at school. Current medications: methylphenidate immediate-release 10 mg tablet at 7 AM and 12 PM. Labs: SCr 0.7 mg/dL (0.6–1.3), AST 23 U/L (10–40), ALT 21 U/L (7–56), Na 140 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). His parent requests a delivery option that improves adherence while maintaining therapeutic coverage during school hours. What is the optimal drug delivery system for this patient?
    Answer: Switch to a long-acting methylphenidate extended-release oral dosage form taken once daily in the morning This question evaluates delivery systems for ADHD medications to address adherence challenges in adolescents. The key patient-specific factor is forgetting midday doses at school, complicating symptom control. Switching to a long-acting extended-release oral form taken once daily is optimal as it provides sustained coverage without school dosing, enhancing compliance and efficacy. Combining doses or using sublingual/crushed forms (choices B, C, D) risks peaks/troughs or altered pharmacokinetics, potentially causing side effects or inefficacy. Immediate-release without extension (choice B) ignores adherence issues. A pharmaceutical pearl is to select extended-release formulations for school-aged patients to minimize disruptions and stigma. For safety and efficacy, titrate doses based on symptom response and monitor for growth or cardiovascular effects.
  12. A 62-year-old man (78 kg) with dysphagia after head and neck cancer radiation is prescribed potassium chloride for hypokalemia. Current medications: potassium chloride 20 mEq extended-release tablets daily, hydrochlorothiazide 25 mg tablet daily. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 25 U/L (10–40), ALT 23 U/L (7–56), Na 134 mEq/L (135–145), K 3.1 mEq/L (3.5–5.0). He asks for a formulation that is easier to take and safer given his swallowing difficulty. Which formulation is most appropriate for this patient?
    Answer: Switch to potassium chloride oral liquid or powder packets for solution, administered with adequate dilution This question tests safe formulation options for electrolytes in patients with swallowing impairments. The key patient-specific factor is dysphagia increasing aspiration risk with solids. Switching to oral liquid or powder packets is most appropriate as it allows dilution and safe administration without choking hazards. Crushing extended-release or splitting enteric-coated (choices A and D) risks mucosal irritation or erratic release, and whole tablets without water (choice C) exacerbates risks. Continuation (choice C) ignores dysphagia. A pearl is to avoid modified-release potassium forms in dysphagia to prevent esophageal injury. For safety and efficacy, dilute liquids adequately and monitor potassium levels to correct hypokalemia without GI harm.
  13. A 45-year-old man (80 kg) with epilepsy is stable on valproic acid delayed-release tablets but now has a jejunostomy (J-tube) and continuous feeds. Current medications: valproic acid delayed-release 500 mg tablet BID, pantoprazole 40 mg tablet daily. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 34 U/L (10–40), ALT 30 U/L (7–56), Na 138 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). The nurse asks what formulation change is most appropriate for J-tube administration. Which formulation is most appropriate for this patient?
    Answer: Switch to an immediate-release valproic acid liquid formulation suitable for enteral administration and adjust administration technique as needed This question assesses formulation suitability for jejunal tube administration in epilepsy management. The key patient-specific factor is the J-tube with continuous feeds, bypassing stomach and potentially affecting delayed-release drugs. Switching to immediate-release valproic acid liquid is best as it allows direct jejunal absorption without release alteration, maintaining seizure control. Crushing delayed-release or using enteric-coated (choices A and C) disrupts pH-dependent release, risking toxicity or inefficacy, and whole administration (choice D) risks occlusion. Continuation without change (choice D) ignores tube compatibility. A pearl is to avoid extended-release forms in distal enteral tubes due to reduced transit time. Emphasizing safety, flush tubes adequately and monitor levels to ensure therapeutic efficacy without GI upset.
  14. A 71-year-old man (76 kg) with atrial fibrillation has a PEG tube and cannot swallow tablets. Current medications: apixaban 5 mg tablet BID, metoprolol tartrate 25 mg tablet BID, furosemide 20 mg tablet daily. Labs: SCr 1.2 mg/dL (0.6–1.3), AST 27 U/L (10–40), ALT 24 U/L (7–56), Na 137 mEq/L (135–145), K 3.8 mEq/L (3.5–5.0). The nurse asks which oral anticoagulant formulation approach is most appropriate for tube administration based on pharmaceutic considerations. Which formulation is most appropriate for this patient?
    Answer: Crush apixaban tablets and administer via PEG with water flushes per institutional policy and available data This question tests formulation adaptations for oral anticoagulants in patients with feeding tubes. The key patient-specific factor is the inability to swallow tablets, requiring tube-compatible administration. Crushing apixaban tablets and administering via PEG with flushes is appropriate per data, as it maintains bioavailability without altering the immediate-release profile. Enteric-coated or extended-release options (choices B and C) are hypothetical or unsuitable for crushing, risking efficacy loss, and whole administration without flushing (choice D) may cause occlusion. Hypothetical capsules (choice C) do not exist for apixaban. A pearl is to consult compatibility resources for tube administration to avoid interactions or blockages. To ensure safety, confirm crushing does not affect stability and monitor coagulation parameters for efficacy.
  15. A 70-year-old woman (64 kg) with chronic pain is prescribed morphine but has difficulty swallowing and frequent nausea. Current medications: ondansetron ODT 4 mg q8h PRN, acetaminophen 500 mg tablet q6h PRN. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 28 U/L (10–40), ALT 25 U/L (7–56), Na 137 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The prescriber wants a non-oral delivery method to improve adherence and maintain steady analgesia. What is the optimal drug delivery system for this patient?
    Answer: Transdermal fentanyl patch (when clinically appropriate) for sustained delivery and reduced pill burden This question examines non-oral delivery options for chronic pain management in patients with GI issues. The key patient-specific factor is difficulty swallowing and nausea, hindering oral adherence. Transdermal fentanyl is optimal for sustained analgesia with reduced pill burden, bypassing GI absorption for steady levels. Frequent oral dosing or crushing extended-release (choices A and C) increases nausea risk or alters release, while sublingual sustained-release (choice D) is unavailable. Immediate-release slurry (choice C) poses safety risks. A pearl is to use transdermal systems for opioid-naive patients cautiously, titrating slowly. For safety and efficacy, monitor for respiratory depression and rotate patch sites to prevent skin irritation.
  16. A 60-year-old male (weight 82 kg) with GERD reports persistent symptoms despite taking omeprazole delayed-release capsules 20 mg by mouth daily; he also takes calcium carbonate chewable tablets as needed and metformin immediate-release tablets 500 mg twice daily. He recently started taking omeprazole by opening the capsule and sprinkling contents into hot coffee to "help it dissolve." Labs: SCr 1.0 mg/dL (0.6–1.3), AST 26 U/L (10–40), ALT 24 U/L (7–56), Na 138 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). The pharmacist suspects reduced exposure due to improper dosage-form handling. Which factor most affects this drug's bioavailability?
    Answer: Destruction of enteric coating leading to acid degradation of the drug before absorption This question evaluates understanding of modified-release formulation integrity. The key patient-specific factor is the improper handling of omeprazole delayed-release capsules by sprinkling contents into hot coffee. The primary issue is destruction of the enteric coating on the pellets, which protects omeprazole from acid degradation in the stomach - exposure to hot liquids damages this coating, leading to drug degradation before it reaches its absorption site in the small intestine. Increased solubility affecting first-pass metabolism is not the mechanism of failure. Chelation with metformin is not a significant interaction for omeprazole. Calcium carbonate can reduce stomach acid but doesn't cause dose dumping of properly intact pellets. The pharmaceutical pearl is that enteric-coated and delayed-release formulations must maintain their coating integrity to ensure drug stability and proper site-specific delivery, and patients should be counseled to never expose these formulations to heat, crushing, or chewing.
  17. A 45-year-old female (weight 64 kg) with Crohn disease status post ileal resection reports worsening neuropathic pain despite adherence. Current medications: gabapentin 600 mg immediate-release tablets by mouth three times daily, ferrous sulfate 325 mg by mouth daily, and pantoprazole delayed-release tablets 40 mg by mouth daily. Labs: SCr 0.9 mg/dL (0.6–1.3), AST 20 U/L (10–40), ALT 19 U/L (7–56), Na 139 mEq/L (135–145), K 4.0 mEq/L (3.5–5.0). The pharmacist is asked which pharmaceutical factor is most likely to affect oral drug bioavailability in a patient with significant small-bowel resection. Which factor most affects this drug's bioavailability?
    Answer: Reduced intestinal surface area decreases the extent of absorption for drugs absorbed in the small intestine This question addresses factors affecting oral drug bioavailability after bowel resection. The key patient-specific factor is the history of ileal resection for Crohn disease, which significantly reduces the intestinal surface area available for drug absorption. Reduced intestinal surface area is the primary factor decreasing the extent of absorption for drugs absorbed in the small intestine, particularly those with site-specific absorption like gabapentin. Increased gastric emptying time would actually increase, not decrease, absorption for most immediate-release drugs by prolonging contact time. Bile salt concentrations typically decrease (not increase) after ileal resection, and while this affects lipophilic drug absorption, it's not the primary factor. Hepatic first-pass metabolism is not directly affected by bowel resection. The pharmaceutical pearl is that patients with significant small bowel resection may require higher doses or more frequent administration of medications to achieve therapeutic effects, and monitoring for therapeutic response is essential.
  18. A 60-year-old man (92 kg) with short bowel syndrome has subtherapeutic levels of an extended-release antihypertensive despite adherence. Current medications: nifedipine extended-release 60 mg tablet daily, lisinopril 20 mg tablet daily. Labs: SCr 1.0 mg/dL (0.6–1.3), AST 23 U/L (10–40), ALT 22 U/L (7–56), Na 136 mEq/L (135–145), K 4.6 mEq/L (3.5–5.0). The pharmacist suspects the dosage form is not being absorbed adequately. Which factor most affects this drug's bioavailability?
    Answer: Decreased gastrointestinal transit time reducing contact time for drug release and absorption This question explores bioavailability challenges of extended-release formulations in altered GI transit conditions. The key patient-specific factor is short bowel syndrome accelerating transit and reducing absorptive time. Decreased GI transit time is the primary factor as it limits drug release from extended-release matrices, leading to subtherapeutic levels. Increased gastric residence or bile secretion (choices B and D) would enhance rather than impair, and renal blood flow (choice C) is unrelated to oral bioavailability. Enhanced performance (choice B) contradicts syndrome effects. A pearl is to prefer immediate-release forms in rapid transit states to ensure adequate exposure. To promote safety, monitor blood pressure and adjust antihypertensives based on clinical response for efficacy.
  19. A 29-year-old woman (66 kg) receives a prescription for nitroglycerin sublingual tablets for angina. Current medications: none. Labs: SCr 0.8 mg/dL (0.6–1.3), AST 19 U/L (10–40), ALT 17 U/L (7–56), Na 139 mEq/L (135–145), K 4.2 mEq/L (3.5–5.0). She asks how to store the tablets because she wants to transfer them into a weekly pill organizer for convenience. How should this medication be stored to maintain stability?
    Answer: Keep tablets in the original, tightly closed glass container protected from light and moisture; do not transfer to pill boxes This question examines storage requirements for volatile medications like nitroglycerin to preserve potency. The key patient-specific factor is the desire to use a pill organizer, which could expose tablets to air and moisture. Keeping tablets in the original tightly closed glass container protected from light and moisture is best as it prevents sublimation and degradation, maintaining sublingual efficacy. Transferring to organizers or storing in humid areas (choices A and C) accelerates potency loss, while refrigeration (choice D) may introduce moisture upon opening. Bathroom storage (choice C) exposes to humidity fluctuations. A pearl is to store volatile drugs in original packaging to minimize environmental exposure and ensure rapid onset. Emphasizing safety, advise patients to replace nitroglycerin every 3-6 months and recognize signs of reduced potency for effective angina relief.
  20. A 35-year-old man (90 kg) with asthma reports poor adherence to a twice-daily inhaled corticosteroid due to a busy schedule. Current medications: budesonide DPI 1 inhalation BID, albuterol HFA 2 puffs q4–6h PRN. Labs: SCr 0.8 mg/dL (0.6–1.3), AST 24 U/L (10–40), ALT 26 U/L (7–56), Na 140 mEq/L (135–145), K 4.1 mEq/L (3.5–5.0). He requests a delivery method that improves compliance while maintaining controller therapy. What is the optimal drug delivery system for this patient?
    Answer: Switch to a once-daily inhaled corticosteroid option delivered via DPI or MDI as appropriate This question evaluates drug delivery systems for asthma controller therapy to enhance adherence. The key patient-specific factor is the busy schedule leading to poor compliance with twice-daily dosing. Switching to a once-daily inhaled corticosteroid via DPI or MDI is best as it simplifies the regimen, improving adherence while maintaining lung-targeted delivery and efficacy. Nebulized or oral options (choices A and C) may reduce convenience or increase systemic effects, and doubling doses (choice D) risks inconsistent control and side effects. Continuing the current DPI without regimen change (choice D) ignores adherence barriers. A key pearl is to match delivery systems to lifestyle factors for chronic conditions to optimize long-term control. Emphasizing safety, pharmacists should assess inhaler technique regularly to ensure effective drug deposition and asthma management.

Start this quiz